8-K
filed January 9, 2026, 6:59 PM ET
ticker BCLI
CIK 0001137883
debt
confidence high
sentiment negative
materiality 0.75
BCLI issues three convertible notes to institutional investors, total ~$329K principal
BRAINSTORM CELL THERAPEUTICS INC.
- Vanquish Funding: $94.3K note (12% OID), convertible at 65% of lowest trading price upon default, matures Oct 2026.
- Quick Capital: $94.9K note (10% OID), convertible at 75% of lowest trading price upon default, matures Jan 2027.
- Auctus Fund: $140K note (12% OID), convertible at 65% of lowest trading price after 6 months or upon default, matures 12 months.
- Notes include default penalties of 150% of outstanding, cross-default provisions, and beneficial ownership limitations at 4.99%.
- Proceeds used for general working capital; issuance exempt under Section 4(a)(2) and Rule 506.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.85
BRAINSTORM CELL THERAPEUTICS INC. issued shares of common stock issuable upon conversion of the Notes of convertible note to accredited investors for not specified.
- Security
- convertible note
- Shares
- shares of common stock issuable upon conversion of the Notes
- Purchaser
- accredited investors
- Consideration
- not specified
Exact text from the filing
The Notes, and the shares of the Company’s common stock issuable upon conversion of the Notes, if any, were or will be issued in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D thereunder.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with Vanquish Funding Group Inc. valued at aggregate principal amount of $94,300 (effective 2025-12-31).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Vanquish Funding Group Inc.
- Value
- aggregate principal amount of $94,300
- Effective
- 2025-12-31
Exact text from the filing
On December 31, 2025, the Company entered into a Securities Purchase Agreement with Vanquish Funding Group Inc., under which the Company issued a note in the aggregate principal amount of $94,300 (including $12,300 original issue discount) for aggregate purchase price proceeds of $82,000
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BRAINSTORM CELL THERAPEUTICS INC. entered into Note Purchase Agreement with Quick Capital, LLC valued at principal amount of $94,875 (effective 2026-01-05).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Quick Capital, LLC
- Value
- principal amount of $94,875
- Effective
- 2026-01-05
Exact text from the filing
On January 5, 2026, the Company entered into a Note Purchase Agreement with Quick Capital, LLC, under which the Company issued a convertible promissory note in the principal amount of $94,875
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BRAINSTORM CELL THERAPEUTICS INC. entered into Securities Purchase Agreement with Auctus Fund, LLC valued at aggregate principal amount of $140,000 (effective 2026-01-06).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Auctus Fund, LLC
- Value
- aggregate principal amount of $140,000
- Effective
- 2026-01-06
Exact text from the filing
On January 6, 2026, the Company entered into a Securities Purchase Agreement with Auctus Fund, LLC, under which the Company issued a convertible promissory note in the aggregate principal amount of $140,000, including a $14,000 original issue discount, for cash proceeds of $126,000
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.